Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Therapeutic management of HIV-infected patients with chronic kidney disease

Abstract

CKD and HIV infection are two chronic diseases impacting heavily on the survival of the affected patients. The interplay between HIV infection and chronic kidney disease (CKD) is complex and interactions occur at multiple levels. Approach to the management of HIV-infected patients requires special attention to face the numerous therapeutic difficulties ranging from drug-drug interactions to drug-toxicity. The most effective strategy is targeted to suppression of HIV viral load, as it dramatically changes the prognosis of the patients as well as prevents the development of HIV-associated kidney disease. As shown in this review, the approach to the therapeutic management of CKD in the setting of HIV infection varies in relation to the degree of renal impairment.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    UNAIDS Science Panel (2018) Making the end of AIDS real: consensus building around what we mean by “epidemic control.” Geneva: UNAIDS. https://www.unaids.org/sites/default/files/media_asset/glion_oct2017_meeting_report_en.pdf, Accessed 4 July 2019. https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf. Accessed 15 Sept 2019

  2. 2.

    Wu P-Y, Hung C-C, Liu W-C et al (2012) Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother 67(4):1001–1009. https://doi.org/10.1093/jac/dkr558

  3. 3.

    Ekrikpo UE, Kengne AP, Bello AK et al (2018) Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS ONE 13(4):e0195443. https://doi.org/10.1371/journal.pone.0195443

  4. 4.

    Lucas GM, Mehta SH, Atta MG et al (2007) End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS Lond Engl 21(18):2435–2443. https://doi.org/10.1097/QAD.0b013e32827038ad

  5. 5.

    Bansi L, Hughes A, Bhagani S et al (2009) Clinical epidemiology of HIV-associated end-stage renal failure in the UK. AIDS Lond Engl 23(18):2517–2521. https://doi.org/10.1097/QAD.0b013e3283320e12

  6. 6.

    Freiberg MS, Chang C-CH, Kuller LH et al (2013) HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173(8):614–622. https://doi.org/10.1001/jamainternmed.2013.3728

  7. 7.

    Pereyra F, Lo J, Triant VA et al (2012) Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS Lond Engl 26(18):2409–2412. https://doi.org/10.1097/QAD.0b013e32835a9950

  8. 8.

    Deeks SG, Tracy R, Douek DC (2013) Systemic effects of inflammation on health during chronic HIV infection. Immunity 39(4):633–645. https://doi.org/10.1016/j.immuni.2013.10.001

  9. 9.

    Ibáñez L, Velli PS, Font R et al (2014) HIV-infection, atherosclerosis and the inflammatory pathway: candidate gene study in a spanish HIV-infected population. PLoS ONE. https://doi.org/10.1371/journal.pone.0112279

  10. 10.

    Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. AIDSinfo. https://aidsinfo.nih.gov/guidelines. Accessed 1 July 2019

  11. 11.

    EACS, Guidelines version 9.1, October 2018.

  12. 12.

    Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.51). Licence: CC BY-NC-SA 3.0 IGO

  13. 13.

    Alfano G, Cappelli G, Fontana F et al (2019) Kidney disease in HIV infection. J Clin Med 8(8):1254. https://doi.org/10.3390/jcm8081254

  14. 14.

    Gara N, Zhao X, Collins MT et al (2012) Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 35(11):1317–1325. https://doi.org/10.1111/j.1365-2036.2012.05093.x

  15. 15.

    Iwata K, Nagata M, Watanabe S, Nishi S (2016) Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharmacol Toxicol. https://doi.org/10.1186/s40360-016-0100-y

  16. 16.

    Casado JL, Bañón S, Santiuste C et al (2016) Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir. AIDS Lond Engl 30(2):231–239. https://doi.org/10.1097/QAD.0000000000000901

  17. 17.

    Lucas GM, Ross MJ, Stock PG et al (2014) Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 59(9):e96–e138. https://doi.org/10.1093/cid/ciu617

  18. 18.

    Custodio JM, Fordyce M, Garner W et al (2016) Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother 60(9):5135–5140. https://doi.org/10.1128/AAC.00005-16

  19. 19.

    Post FA, Tebas P, Clarke A et al (2017) Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 1999 74(2):180–184. https://doi.org/10.1097/QAI.0000000000001186

  20. 20.

    Mills A, Arribas JR, Andrade-Villanueva J et al (2016) Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16(1):43–52. https://doi.org/10.1016/S1473-3099(15)00348-5

  21. 21.

    Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huhn G (2016) Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy 36(9):e148–153. https://doi.org/10.1002/phar.1803

  22. 22.

    Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG (2017) Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine (Baltimore). 96(36):e8046. https://doi.org/10.1097/MD.0000000000008046

  23. 23.

    Bahr NC, Yarlagadda SG (2019) Fanconi Syndrome and tenofovir alafenamide: a case report. Ann Intern Med 170(11):814. https://doi.org/10.7326/L18-0592

  24. 24.

    Tattevin P, Revest M, Chapplain J-M, Ratajczak-Enselme M, Arvieux C, Michelet C (2013) Increased risk of renal stones in patients treated with atazanavir. Clin Infect Dis Off Publ Infect Dis Soc Am 56(8):1186. https://doi.org/10.1093/cid/cis1211

  25. 25.

    Izzedine H, Lescure FX, Bonnet F (2014) HIV medication-based urolithiasis. Clin Kidney J 7(2):121–126. https://doi.org/10.1093/ckj/sfu008

  26. 26.

    de Lastours V, Ferrari Rafael De Silva E, Daudon M et al (2013) High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 68(8):1850–1856. https://doi.org/10.1093/jac/dkt125

  27. 27.

    Friis-Møller N, Weber R, Reiss P et al (2003) Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS Lond Engl 17(8):1179–1193. https://doi.org/10.1097/01.aids.0000060358.78202.c1

  28. 28.

    Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL (2018) Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents 52(5):541–553. https://doi.org/10.1016/j.ijantimicag.2018.07.010

  29. 29.

    Palacios R, Mayorga M, González-Domenech CM et al (2018) Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study. J Int Assoc Provid AIDS Care JIAPAC. https://doi.org/10.1177/2325958218760847

  30. 30.

    Jabłonowska E, Siwak E, Bociąga-Jasik M et al (2019) Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PLoS ONE 14(1):e0210476. https://doi.org/10.1371/journal.pone.0210476

  31. 31.

    Taiwo BO, Marconi VC, Berzins B et al (2018) Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis Off Publ Infect Dis Soc Am 66(11):1794–1797. https://doi.org/10.1093/cid/cix1131

  32. 32.

    Levey AS, Stevens LA (2010) Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis Off J Natl Kidney Found 55(4):622–627. https://doi.org/10.1053/j.ajkd.2010.02.337

  33. 33.

    Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis Off J Natl Kidney Found 40(2):221–226. https://doi.org/10.1053/ajkd.2002.34487

  34. 34.

    Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 3:1–150. 93. https://www.kidney-international.org/article/S0085-2538(18)30118-2/abstract. Accessed 18 Nov 2018

  35. 35.

    Ki-Chul S, Seungho R, Jong-Young L et al (2016) Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. J Am Heart Assoc 5(9):e003245. https://doi.org/10.1161/JAHA.116.003245

  36. 36.

    Inker LA, Astor BC, Fox CH et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis Off J Natl Kidney Found 63(5):713–735. https://doi.org/10.1053/j.ajkd.2014.01.416

  37. 37.

    Swanepoel CR, Atta MG, D’Agati VD et al (2018) Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 93(3):545–559. https://doi.org/10.1016/j.kint.2017.11.007

  38. 38.

    EACS Guidelines as follows: EACS Guidelines version 10.0 (2019) https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed 22 Dec 2019

  39. 39.

    Delanaye P, Jager KJ, Bökenkamp A et al (2019) CKD: a call for an age-adapted definition. J Am Soc Nephrol JASN 30(10):1785–1805. https://doi.org/10.1681/ASN.2019030238

  40. 40.

    Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertens Dallas Tex 1979 71(6):1269–1324. https://doi.org/10.1161/HYP.0000000000000066

  41. 41.

    Rosenson RS, Colantonio LD, Burkholder GA, Chen L, Muntner P (2018) Trends in utilization of statin therapy and contraindicated statin use in HIV–infected adults treated with antiretroviral therapy from 2007 through 2015. J Am Heart Assoc 7(24):e010345. https://doi.org/10.1161/JAHA.118.010345

  42. 42.

    Research C for DE and FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine). FDA (2019) https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-serious-liver-disorder-associated-use-videxvidex-ec-didanosine. Accessed 25 July 2019

  43. 43.

    Fichtenbaum CJ, Gerber JG (2002) Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41(14):1195–1211. https://doi.org/10.2165/00003088-200241140-00004

  44. 44.

    Song IH, Zong J, Borland J et al (2016) The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr 1999 72(4):400–407. https://doi.org/10.1097/QAI.0000000000000983

  45. 45.

    Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56(3):305–314. https://doi.org/10.1046/j.0306-5251.2003.01862.x

  46. 46.

    May M, Schindler C (2016) Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab 7(2):69–83. https://doi.org/10.1177/2042018816638050

  47. 47.

    Trullas JC, Mocroft A, Cofan F et al (2010) Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr 1999 55(5):582–589. https://doi.org/10.1097/QAI.0b013e3181efbe59

  48. 48.

    Rastegar DA, Knight AM, Monolakis JS (2006) Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis Off Publ Infect Dis Soc Am 43(7):933–938. https://doi.org/10.1086/507538

  49. 49.

    Tourret J, Tostivint I, Du Montcel ST et al (2007) Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. Clin Infect Dis Off Publ Infect Dis Soc Am 45(6):779–784. https://doi.org/10.1086/521168

  50. 50.

    Achenbach CJ, Darin KM, Murphy RL, Katlama C (2011) Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 6(2):157–177. https://doi.org/10.2217/fvl.10.89

  51. 51.

    Eron JJ, Lelievre J-D, Kalayjian R et al (2018) Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV. https://doi.org/10.1016/S2352-3018(18)30296-0

  52. 52.

    Michienzi SM, Schriever CA, Badowski ME (2019) Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS 30(2):181–187. https://doi.org/10.1177/0956462418800865

  53. 53.

    Schloth T, Genabe I, Pilgrim W, Jorden A, Fein PA, Avram MM (1992) Peritonitis and the patient with human immunodeficiency virus (HIV). Adv Perit Dial Conf Perit Dial 8:250–252

  54. 54.

    Dressler R, Peters AT, Lynn RI (1989) Pseudomonal and candidal peritonitis as a complication of continuous ambulatory peritoneal dialysis in human immunodeficiency virus-infected patients. Am J Med 86(6 Pt 2):787–790. https://doi.org/10.1016/0002-9343(89)90474-9

  55. 55.

    Punyawudho B, Singkham N, Thammajaruk N et al (2016) Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Rev Clin Pharmacol 9(12):1583–1595. https://doi.org/10.1080/17512433.2016.1235972

  56. 56.

    Ndlovu KCZ, Assounga A (2017) Continuous ambulatory peritoneal dialysis in patients with hiv and end-stage renal failure. Perit Dial Int J Int Soc Perit Dial 37(3):321–330. https://doi.org/10.3747/pdi.2016.00165

  57. 57.

    Locke JE, Gustafson S, Mehta S et al (2017) Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg 265(3):604–608. https://doi.org/10.1097/SLA.0000000000001761

  58. 58.

    Locke JE, Mehta S, Reed RD et al (2015) A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol JASN 26(9):2222–2229. https://doi.org/10.1681/ASN.2014070726

  59. 59.

    Stock PG, Barin B, Murphy B et al (2010) Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 363(21):2004–2014. https://doi.org/10.1056/NEJMoa1001197

  60. 60.

    Alfano G, Mori G, Fontana F et al (2018) Clinical outcome of kidney transplantation in HIV-infected recipients: a retrospective study. Int J STD AIDS 29(13):1305–1315. https://doi.org/10.1177/0956462418779659

  61. 61.

    Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM (2003) Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 170(8):4077–4086. https://doi.org/10.4049/jimmunol.170.8.4077

  62. 62.

    Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155. https://doi.org/10.1146/annurev-med-042909-093756

  63. 63.

    Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP (1992) Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 8(9):1641–1652. https://doi.org/10.1089/aid.1992.8.1641

  64. 64.

    Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG (2006) Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 6(4):753–760. https://doi.org/10.1111/j.1600-6143.2006.01238.x

  65. 65.

    van Leeuwen MT, Grulich AE, Webster AC et al (2009) Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 114(3):630–637. https://doi.org/10.1182/blood-2009-02-202507

  66. 66.

    Müller TF, Grebe SO, Neumann MC et al (1997) Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 64(10):1432–1437. https://doi.org/10.1097/00007890-199711270-00010

  67. 67.

    Kucirka LM, Durand CM, Bae S et al (2016) Induction immunosuppression and clinical outcomes in HIV-infected kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 16(8):2368–2376. https://doi.org/10.1111/ajt.13840

  68. 68.

    Blumberg EA, Rogers CC (2013) Human immunodeficiency virus in solid organ transplantation. Am J Transplant 13(s4):169–178. https://doi.org/10.1111/ajt.12109

  69. 69.

    Fumero E, García F, Gatell JM (2004) Immunosuppressive drugs as an adjuvant to HIV treatment. J Antimicrob Chemother 53(3):415–417. https://doi.org/10.1093/jac/dkh123

  70. 70.

    Chapuis AG, Paolo Rizzardi G, D’Agostino C et al (2000) Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 6(7):762–768. https://doi.org/10.1038/77489

  71. 71.

    Alfano G, Fontana F, Mori G et al (2019) Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. Int J STD AIDS 30(9):919–922. https://doi.org/10.1177/0956462419839520

  72. 72.

    Perez CP, Patel N, Mardis CR, Meadows HB, Taber DJ, Pilch NA (2018) Belatacept in solid organ transplant: review of current literature across transplant types. Transplantation 102(9):1440–1452. https://doi.org/10.1097/TP.0000000000002291

  73. 73.

    Ebcioglu Z, Liu C, Shapiro R et al (2016) Belatacept conversion in an HIV-positive kidney transplant recipient with prolonged delayed graft function. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 16(11):3278–3281. https://doi.org/10.1111/ajt.13923

  74. 74.

    Marfo K, Greenstein S (2009) Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc 41(9):3796–3799. https://doi.org/10.1016/j.transproceed.2009.06.186

  75. 75.

    Mahalati K, Kahan BD (2001) Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40(8):573–585. https://doi.org/10.2165/00003088-200140080-00002

  76. 76.

    White AJ (2001) Mitochondrial toxicity and HIV therapy. Sex Transm Infect 77(3):158–173. https://doi.org/10.1136/sti.77.3.158

  77. 77.

    Sawinski D, Shelton BA, Mehta S et al (2017) Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 17(12):3114–3122. https://doi.org/10.1111/ajt.14419

  78. 78.

    Blumberg EA, Rogers CC (2013) AST infectious diseases community of practice. Human immunodeficiency virus in solid organ transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 13(Suppl 4):169–178. https://doi.org/10.1111/ajt.12109

  79. 79.

    Segerer S, Mack M, Regele H, Kerjaschki D, Schlöndorff D (1999) Expression of the C-C chemokine receptor 5 in human kidney diseases1. Kidney Int 56(1):52–64. https://doi.org/10.1046/j.1523-1755.1999.00544.x

  80. 80.

    Frassetto LA, Tan-Tam C, Stock PG (2009) Renal transplantation in patients with HIV. Nat Rev Nephrol 5(10):582–589. https://doi.org/10.1038/nrneph.2009.140

  81. 81.

    Izzo I, Casari S, Bossini N et al (2018) Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy). Infection 46(1):77–82. https://doi.org/10.1007/s15010-017-1092-2

  82. 82.

    Sawinski D, Kaur N, Ajeti A et al (2016) Successfultreatment of hepa titis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 16(5):1588–1595. https://doi.org/10.1111/ajt.13620

  83. 83.

    Benhamou Y, Bochet M, Di Martino V et al (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatol Baltim Md 30(4):1054–1058. https://doi.org/10.1002/hep.510300409

  84. 84.

    Mocroft A, Neuhaus J, Peters L et al (2012) Hepatitis B and C Co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS ONE 7(7):e40245. https://doi.org/10.1371/journal.pone.0040245

  85. 85.

    Chang T-T, Lai C-L, Chien R-N et al (2004) Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19(11):1276–1282. https://doi.org/10.1111/j.1440-1746.2004.03428.x

  86. 86.

    Chang T-T, Gish RG, de Man R et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001–1010. https://doi.org/10.1056/NEJMoa051285

  87. 87.

    Agarwal K, Brunetto M, Seto WK et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672–681. https://doi.org/10.1016/j.jhep.2017.11.039

  88. 88.

    Izzedine H, Hulot JS, Launay-Vacher V et al (2004) Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66(3):1153–1158. https://doi.org/10.1111/j.1523-1755.2004.00866.x

  89. 89.

    Fabrizi F, Messa P (2018) Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 11(11):1135–1142. https://doi.org/10.1080/17512433.2018.1534202

  90. 90.

    Aggarwal A, Yoo ER, Perumpail RB et al (2017) Sofosbuvir use in the setting of end-stage renal disease: a single center experience. J Clin Transl Hepatol 5(1):23–26. https://doi.org/10.14218/JCTH.2016.00060

  91. 91.

    Li M, Chen J, Fang Z, Li Y, Lin Q (2019) Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virol J 16(1):34. https://doi.org/10.1186/s12985-019-1140-x

  92. 92.

    Gane E, Lawitz E, Pugatch D et al (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377(15):1448–1455. https://doi.org/10.1056/NEJMoa1704053

  93. 93.

    Rockstroh JK, Lacombe K, Viani RM et al (2018) Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis Off Publ Infect Dis Soc Am 67(7):1010–1017. https://doi.org/10.1093/cid/ciy220

  94. 94.

    Roth D, Nelson DR, Bruchfeld A et al (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet 386(10003):1537–1545. https://doi.org/10.1016/S0140-6736(15)00349-9

  95. 95.

    Recommendations for Testing, Managing, and Treating Hepatitis C | HCV Guidance. https://www.hcvguidelines.org/. Accessed 7 August 2019

  96. 96.

    Sherer R, Stieglitz K, Narra J et al (2002) HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care 14(Suppl 1):S31–44. https://doi.org/10.1080/09540120220149975

Download references

Author information

Correspondence to Gaetano Alfano.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent is not applicable because this study is a review.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alfano, G., Guaraldi, G., Fontana, F. et al. Therapeutic management of HIV-infected patients with chronic kidney disease. J Nephrol (2020). https://doi.org/10.1007/s40620-020-00701-8

Download citation

Keywords

  • HIV
  • Chronic kidney disease
  • Antiretroviral therapy
  • Dialysis
  • Kidney transplantation
  • Kidney waiting list